with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
No takes yet. Share an insight, caveat, or question.
Hoffman et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: